Cryo-Cell International, Inc. - 10-Q Summary
Business Context and Reporting Period
Company: Cryo-Cell International, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: August 31, 2008
Business Overview: The Company is engaged in cellular processing and cryogenic storage, primarily focusing on the collection and preservation of umbilical cord blood stem cells (U-Cord®) for family use. It also markets the C'elle™ service for menstrual stem cells and holds licensing agreements in international markets including India and Venezuela.
Key Financial Metrics
| Metric | Nine Months Ended Aug 31, 2008 | Nine Months Ended Aug 31, 2007 |
|---|---|---|
| Revenue | $13,143,831 | $13,173,166 |
| Net Loss | $(792,308) | $(3,338,062) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.29) |
| Operating Cash Flow | $177,203 | $(3,083,408) |
| Cash and Cash Equivalents (End of Period) | $3,304,465 | $3,747,166 |
| Total Assets | $10,920,839 | $11,633,709 |
| Total Liabilities | $17,995,388 | $18,224,391 |
| Stockholders' Deficit | $(7,074,549) | $(6,590,682) |
Debt and Liquidity: As of October 14, 2008, the Company maintains no indebtedness. The Company anticipates that cash, marketable securities, and operating cash flows will be sufficient to fund operations for at least the next 12 months. Capital expenditures are anticipated to be approximately $500,000 over the next twelve months.
Material Changes vs. Prior Period
- Revenue: Decreased less than 1% year-over-year. This was driven by a 12% decrease in specimens processed, partially offset by a 16% increase in recurring annual storage fee revenue and a 21% decrease in sales discounts.
- Net Loss: Significantly improved, decreasing from $3.34 million to $0.79 million. This reduction is attributed to a 22% decrease in marketing, general, and administrative expenses (primarily due to a 56% drop in professional fees related to a prior proxy contest) and a 66% decrease in research and development expenses.
- Operating Cash Flow: Turned positive, providing $177,203 compared to a use of $3.08 million in the prior year. This improvement was driven by the receipt of approximately $189,000 from sub-license agreement sales.
- Interest Expense: Increased to $988,581 from $847,402, primarily due to payments under Revenue Sharing Agreements (RSAs) based on storage revenue.
Guidance, Outlook, and Risks
Management Commentary: Management expects cash resources to be sufficient for the next 12 months. The Company is focusing on the commercialization of the C'elle™ service and new menstrual stem cell technologies. The indefinite postponement of the Plureon fetal placental stem cell service in 2007 contributed to lower R&D expenses in the current period.
Risks and Contingencies:
- Legal Proceedings: The Company is involved in patent litigation with PharmaStem Therapeutics, Inc. regarding stem cell patents. While a previous round of litigation resulted in a favorable judgment for Cryo-Cell (patents held invalid), a second round of litigation remains stayed pending reexamination proceedings.
- Warranty Reserves: The Company maintains reserves for a product warranty program (up to $50,000 per unit for engraftment failure) and the Cryo-Cell Cares™ program. As of August 31, 2008, reserves totaled approximately $97,000. A small increase in usage or failure rates could significantly impact these reserves.
- Revenue Sharing Agreements (RSAs): The Company has perpetual RSAs covering specific geographic areas (NY, TX, FL, IL). Interest expense will increase if storage revenues in these areas grow.
- Market Acceptance: Future performance depends on the market acceptance of the C'elle service and the development of new therapies, which are not certain.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 16% increase in recurring storage fees versus the 12% decline in new specimen processing.
- Legal Exposure: Monitor the status of the reexamination proceedings for PharmaStem's patents ('645 and '427) which could impact future litigation costs or royalties.
- Warranty Liability: Review the assumptions used for the $97,000 warranty reserve, as the Company notes that historical failure rates are low and a small increase could cause a significant reserve adjustment.
- Liquidity Runway: Confirm that the projected $500,000 capital expenditure and ongoing operating losses do not deplete the $3.3 million cash balance faster than anticipated.
- License Income: Track the collection of the remaining $150,000 installment from the LifeCell India agreement and the $100,000 from the Venezuela agreement.